Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17328219 | 0.88 | EPHX2 (0.43) | POLBKDM4EEPHX2IDO1MAPT | |
| SCHEMBL19107366 | 0.88 | EPHX2 (0.43) | POLBKDM4EEPHX2IDO1MAPT | |
| SCHEMBL17328224 | 0.86 | KMT2A (0.46) | KDM4EALDH1A1MEN1KMT2ASCD5 | |
| SCHEMBL19107369 | 0.85 | POLB (0.49) | POLBALDH1A1EPHX2IDO1MEN1 | |
| SCHEMBL20058330 | 0.85 | HPGD (0.42) | POLBEPHX2IDO1MAPTTP53 | |
| SCHEMBL20598279 | 0.82 | MEN1 (0.47) | KDM4EALDH1A1MEN1KMT2ASCD5 | |
| SCHEMBL18785083 | 0.82 | MEN1 (0.47) | KDM4EALDH1A1MEN1KMT2ASCD5 | |
| SCHEMBL20598448 | 0.82 | MEN1 (0.47) | KDM4EALDH1A1MEN1KMT2ASCD5 | |
| SCHEMBL18785081 | 0.82 | MEN1 (0.47) | KDM4EALDH1A1MEN1KMT2ASCD5 | |
| SCHEMBL17328260 | 0.82 | GPR119 (0.45) | POLBALDH1A1EPHX2SCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170197984-A1 | AMIDE DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-07-13 | — | — | US | disclosed |
| US-20170197984-A1 | AMIDE DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197984-A1 | AMIDE DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRD1, SIGMAR1, OPRM1 | POLB 1747/4885KDM4E 2379/4885ALDH1A1 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.